Bone marrow transplantation

publication venue for

Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. 2022
Precision medicine results from equitable representation. 2024
T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. 2023
The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. 2022
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant.. 57. 2022
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.. 57. 2022
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.. 57. 2021
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.. 56. 2021
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.. 56. 2021
The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. 2021
Cord blood transplants supported by unrelated donor CD34⁺ progenitor cells.. 55. 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.. 55. 2020
Acute respiratory failure and the kinetics of neutrophil recovery in pediatric hematopoietic cell transplantation: a multicenter study.. 55. 2019
Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies.. 55. 2019
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.. 54. 2019
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).. 54. 2019
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients.. 54. 2018
The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.. 54. 2018
End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.. 54. 2018
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.. 54. 2018
The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.. 54. 2018
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.. 53. 2018
No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.. 53. 2017
Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.. 52. 2017
Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors.. 52. 2017
Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.. 52. 2017
Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.. 51. 2016
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.. 51. 2016
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.. 51. 2016
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.. 51. 2016
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.. 50. 2015
Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.. 50. 2015
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.. 50. 2015
Arrhythmias in the setting of hematopoietic cell transplants.. 50. 2015
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.. 50. 2015
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.. 50. 2015
Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.. 50. 2015
KIR and HLA genotypes have no identifiable role in single-unit dominance following double-unit umbilical cord blood transplantation.. 50. 2014
Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.. 49. 2014
Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection.. 49. 2014
Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.. 49. 2014
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.. 48. 2013
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.. 48. 2013
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.. 48. 2012
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.. 48. 2012
Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.. 48. 2012
Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years.. 48. 2012
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.. 47. 2012
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.. 47. 2012
Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.. 47. 2011
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.. 47. 2011
Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation.. 47. 2011
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.. 47. 2011
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.. 47. 2011
Prognostic value of response after upfront therapy for acute GVHD.. 47. 2011
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.. 46. 2010
Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries.. 46. 2010
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.. 45. 2010
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.. 45. 2010
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.. 45. 2009
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.. 45. 2009
CR represents an early index of potential long survival in multiple myeloma.. 45. 2009
Barriers to mental health service use among hematopoietic SCT survivors.. 45. 2009
Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study.. 44. 2009
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.. 43. 2009
Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units.. 43. 2009
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.. 43. 2009
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.. 43. 2008
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.. 42. 2008
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research.. 41. 2007
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.. 40. 2007
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.. 40. 2007
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.. 40. 2007
Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation.. 40. 2007
Symptom burden in patients undergoing autologous stem-cell transplantation.. 39. 2007
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.. 39. 2007
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.. 39. 2007
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.. 38. 2006
Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy.. 38. 2006
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.. 38. 2006
High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.. 37. 2006
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.. 37. 2006
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.. 37. 2006
A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research.. 36. 2005
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.. 36. 2005
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.. 35. 2005
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.. 35. 2005
Outcome of unrelated transplants in patients with multiple myeloma.. 35. 2005
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.. 35. 2005
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.. 35. 2005
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.. 34. 2004
Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.. 34. 2004
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.. 34. 2004
Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation.. 34. 2004
CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.. 34. 2004
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.. 34. 2004
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.. 33. 2004
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.. 33. 2004
Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy.. 33. 2004
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.. 32. 2003
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.. 32. 2003
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.. 32. 2003
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.. 32. 2003
High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation.. 31. 2003
Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.. 31. 2003
Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.. 31. 2003
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.. 30. 2002
Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection.. 29. 2002
Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions.. 28. 2001
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.. 28. 2001
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.. 28. 2001
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.. 27. 2001
High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia.. 27. 2001
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.. 27. 2001
Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.. 27. 2001
Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.. 27. 2001
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.. 27. 2001
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).. 27. 2001
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.. 27. 2001
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.. 26. 2000
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.. 26. 2000
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.. 26. 2000
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.. 25. 2000
Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy).. 25 Suppl 2. 2000
Disseminated toxoplasmosis following T cell-depleted related and unrelated bone marrow transplantation.. 25. 2000
High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.. 25. 2000
Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.. 25. 2000
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.. 24. 1999
Toxicity of single daily dose gentamicin in stem cell transplantation.. 24. 1999
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.. 23. 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.. 23. 1999
Differential growth patterns in SCID mice of patient-derived chronic myelogenous leukemias.. 22. 1998
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.. 20. 1997
Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.. 20. 1997
Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.. 20. 1997
Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis.. 20. 1997
Allogeneic blood stem cell transplantation in advanced hematologic cancers.. 19. 1997
Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.. 19. 1997
Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.. 19. 1997
Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.. 18. 1996
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.. 18. 1996
Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma.. 18. 1996
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.. 17. 1996
Density enrichment and characterization of hematopoietic progenitors and stem cells from umbilical cord blood.. 17. 1996
Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?. 15. 1995
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.. 15. 1995
Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation.. 15. 1995
Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation.. 15. 1995
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.. 14. 1994
Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta.. 14. 1994
Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure.. 14. 1994
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.. 14. 1994
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.. 14. 1994
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.. 13. 1994
Clinical and laboratory comparison study of refrigerated and cryopreserved bone marrow for transplantation.. 13. 1994
Propantheline prevention of mucositis from etoposide.. 12. 1993
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.. 11. 1993
Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow.. 10. 1992
Hemopoietic stem cell processing: comparison of progenitor cell recovery using the Cobe 2991 cell washer and the Haemonetics V50 apheresis system.. 9. 1992
Autologous bone marrow transplant using 4-HC, VP-16 purged bone marrow for acute non-lymphoblastic leukemia.. 4 Suppl 1. 1989
Idarubicin in acute leukemia: results of US trials.. 4 Suppl 1. 1989
Optimal conditions for in vitro T cell depletion of human bone marrow by Campath-1a plus complement as demonstrated by limiting dilution analysis.. 4. 1989
Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC).. 4 Suppl 1. 1989
Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.. 3. 1988
Proceedings of the XIVth annual meeting of the European Cooperative Group for Bone Marrow Transplantation. 10-13 April 1988, Chamonix, France. Abstracts.. 3 Suppl 1. 1988
Bone marrow transplantation for acute non-lymphocytic leukemia: a report from the Childrens Cancer Study Group of sixty-seven children transplanted in first remission.. 2. 1987
Effects of low dose rate irradiation on human marrow hematopoietic and microenvironmental cells: sparing effect upon survival of stromal and leukemic cells.. 2. 1987
Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series.. 55. 2020
Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis.. 54. 2018
Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience.. 53. 2018
Severe pembrolizumab-associated neutropenia after CD34⁺ selected allogeneic hematopoietic-cell transplantation for multiple myeloma.. 53. 2018
Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.. 53. 2018
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients.. 51. 2016
T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia.. 47. 2011
CMV encephalitis in BMT recipients.. 47. 2011
Posterior reversible encephalopathy syndrome due to sirolimus.. 39. 2007
Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.. 35. 2005
Against the odds: haplo-cord grafts protect from GvHD and relapse. 2017
Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD from thrombotic microangiopathy following allogenic transplantation. 2023
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). 2023
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. 2022
Analysis of the CD34+ cell to total nucleated cell content ratio of 619 transplanted and back-up cord blood units. 2020
Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. 2020
Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. 2020
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34⁺ selected graft. 2019
Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation. 2019
Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. 2018
A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. 2014
Successful unrelated donor cord blood transplantation for adult sickle cell disease and Hodgkin lymphoma. 2009
Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT. 2008
Chimerism does not predict for outcome after alemtuzumab based conditioning. 2007
Severe intestinal graft-versus-host disease following autologous stem cell transplantation. 2006
Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.. 53. 2017
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. 2020
Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. 2018
Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. 2018
A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions. 2016
Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections. 2016
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? 2015
Clinical guide to fertility preservation in hematopoietic cell transplant recipients. 2014
Light-chain amyloidosis: SCT, novel agents and beyond. 2012
Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. 2006
Radioimmunoconjugates in acute leukemia treatment: the future is radiant. 2005
Comorbidity indices in hematopoietic stem cell transplantation: a new report card. 2005
High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. 1992
Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. 2019
Prevention and treatment of relapse after stem cell transplantation with immunotherapy. 2018
Live (vaccines) from New York. 2012
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. 2007
Stem cell transplantation in follicular lymphoma: progress at last? 2004

VIVO Weill Cornell Medical College

Bone marrow transplantation Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)